Close Window

Digital Look Email A Friend

Sareum reports positive results from TYK2 programme

Published by Josh White on 24th October 2016

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday.

URL: http://www.digitallook.com/dl/news/story/25120459/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.